HOME >> BIOLOGY >> NEWS
Clinical study reports findings of combination therapy with DOXIL

treatment regimen without compromising efficacy.

"This phase II study evaluated DVd as an alternative to the VAD regimen. With DVd, DOXIL is administered as a one hour infusion (compared to a 96 hour infusion with VAD, which also requires indwelling venous access), and vincristine as an IV push every 28 days. The results from this study are encouraging and further study of the DVd regimen in multiple myeloma is warranted," said Mohamad A. Hussein, M.D., Director of the Multiple Myeloma Research Program at the Cleveland Clinic Taussig Cancer Center, the lead investigator of the study.

About Multiple Myeloma and DOXIL
There are more than 14,600 new cases of myeloma in the U.S. each year, representing 20 percent of blood cancers and 1 percent of all types of cancer. Multiple myeloma is a cancer of plasma cells. Plasma cells are normally present in the bone marrow and are responsible for antibody production in response to infection and other immune triggering events. In myeloma, a defective plasma cell (myeloma cell) gives rise to the much larger number of myeloma cells which build up in the bone marrow. This process disrupts the normal immune system as well as displacing the normal bone marrow cells. 1

Indication
DOXIL is indicated for the treatment of metastatic carcinoma of the ovary in patients with disease that is refractory to both paclitaxel- and platinum-based chemotherapy regimens. Refractory disease is defined as disease that has progressed while on treatment, or within 6 months of completing treatment. DOXIL also is indicated for the treatment of AIDS-related Kaposi's sarcoma in patients with disease that has progressed on prior combination chemotherapy or in patients who are intolerant to such therapy.

These indications are based on objective tumor response rates. No results are available from controlled trials that demonstrate a clinical benefit resulting from this treatment, suc
'"/>


8-May-2003


Page: 1 2 3 4 5 6

Related biology news :

1. Creation of the UK Clinical Research Collaboration will boost clinical trials in UK
2. Clinical judgement still counts strongly alongside genetic testing
3. Jay Levy honored with 2004 Abbott Laboratories Award in Clinical and Diagnostic Immunology
4. Melvin Weinstein wins 2004 BD Award for Research in Clinical Microbiology
5. DFG to establish seven new Clinical Research Units
6. Clinical trial patients dont care about study sponsors or physician conflicts of interest
7. NIH establishes Rare Diseases Clinical Research Network
8. Clinical study results published in NEJM show promising data on Antegren (natalizumab)
9. Clinical trial shows timing of chemotherapy improves survival in breast cancer
10. Clinical services must catch up
11. Clinical Advances towards the simplification if HIV therapy: First once-daily dosing results for the HIV protease inhibitor, Agenerase

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Clinical study reports findings combination therapy with DOXIL

(Date:10/29/2014)... consequence of chemotherapy will benefit from a major research ... prevents hair loss. , The research is being now ... manufacturing company, Paxman Coolers, of Fenay Bridge, Huddersfield, in ... Huddersfield. , The research will be led by key ... pharmacology of cancer treatment, which he will use towards ...
(Date:10/29/2014)... but they also need protection from its harmful rays, just ... in plants that shields them from sun damage. Now, in ... Society , one team reports on the mechanics of how ... at Purdue University note that the harsh ultraviolet radiation plants ... DNA and, as a result, hinder plant growth. Biochemical ...
(Date:10/29/2014)... German . ... Peter Schlögelhofer at the Max F. Perutz Laboratories (MFPL) ... of Vienna dived into the process of meiosis in ... an inversion of the standard meiotic phases. The researchers ... Nature Communications . , Meiosis is the two-step series ...
Breaking Biology News(10 mins):New technology on the way to aid cancer suffers who lose their hair after chemotherapy 2Meiotic cell division 'the other way round' 2
(Date:10/30/2014)... (PRWEB) October 30, 2014 The report ... Chemicals), by Application (Cosmetics & Toiletries, and Soaps & ... to 2019”, has defined and segmented the Fragrance Ingredients ... trends in terms of value. The market has been ... North America, Europe, Asia-Pacific, Latin America, and Rest of ...
(Date:10/30/2014)... 2014 Deep Research Report on Global ... and in-depth research report on the China Naltrexone ... including its definition, classification, application, and industry chain ... covers the international market analysis, including China’s domestic ... macroeconomic environment & economic situation analysis. The report ...
(Date:10/30/2014)... James Sherley says he has been working ... cell technology since his days as a principal investigator at ... late 1990’s. Sherley founded the ASCTC as a new ... the intellectual property developed in Sherley’s research over the years ... of Technology (MIT), and more recently as a senior scientist ...
(Date:10/30/2014)... October 30, 2014 Grace Century portfolio project, ... A. Manganello, Chairman of the Board, to the National ... The appointment was made by the Ministry of Health on ... 2014. , More than a year after Bahamian ... , Prime Minister Perry Christie said the government has completed ...
Breaking Biology Technology:Fragrance Ingredients Market worth $17,104.21 Million by 2019 - New Report by MarketsandMarkets 2Fragrance Ingredients Market worth $17,104.21 Million by 2019 - New Report by MarketsandMarkets 3Fragrance Ingredients Market worth $17,104.21 Million by 2019 - New Report by MarketsandMarkets 4Fragrance Ingredients Market worth $17,104.21 Million by 2019 - New Report by MarketsandMarkets 5Naltrexone HCL Market & Nalbuphine HCL Industry Analysis for Global, China Regions Now at DeepResearchReports.com 2Naltrexone HCL Market & Nalbuphine HCL Industry Analysis for Global, China Regions Now at DeepResearchReports.com 3Boston’s Adult Stem Cell Technology Center, LLC Introduces A New Technology for Monitoring Previously Elusive Adult Stem Cells 2Boston’s Adult Stem Cell Technology Center, LLC Introduces A New Technology for Monitoring Previously Elusive Adult Stem Cells 3Boston’s Adult Stem Cell Technology Center, LLC Introduces A New Technology for Monitoring Previously Elusive Adult Stem Cells 4Grace Century’s Stem Cell Biobank Project Announces Chairman’s Appointment to National Stem Cell Ethics Committee of The Bahamas 2Grace Century’s Stem Cell Biobank Project Announces Chairman’s Appointment to National Stem Cell Ethics Committee of The Bahamas 3
Cached News: